Willow Tree Research initiates coverage of Novo Nordisk with a BUY rating and a $68 price target, citing the attractive valuation. The launch of oral Wegovy is expanding the obesity treatment market rather than just replacing injectable versions, supported by strong prescription growth and efficacy. Pipeline drugs like high-dose Wegovy and others offer future growth but face challenges in efficacy and tolerability. Novo Nordisk's strong cash flow and balance sheet reduce financial risks, though competition, pricing pressure, and the 2032 patent expiration of semaglutide remain key risks.
Novo Nordisk's adjusted revenue fell 10.3% year-over-year, mainly due to weaker sales of Ozempic and Rybelsus, although profitability and cash flow have improved. The company’s drug pipeline in obesity and diabetes shows promise with candidates like ...
Novo Resources Corp's initial reverse circulation drilling at its Wyloo Polymetallic Project in Western Australia uncovered a significant hydrothermal alteration system with high-grade silver and antimony mineralisation from surface. This discovery i...
Eli Lilly announced plans to file for FDA approval of retatrutide, a new weight-loss drug, following phase 3 trials where participants lost an average of nearly 56 pounds over 80 weeks. The drug targets multiple hormones affecting appetite and metabo...
Novo Resources has filed a technical report confirming the mineral resource estimate for the Leven Star Reef gold project in Victoria, Australia, matching earlier estimates. Additionally, drilling at the Wyloo Polymetallic Project in Western Australi...
Novo Resources Corp. has filed a technical report on the Mineral Resource Estimate for the Leven Star Reef at its 100% owned Belltopper Gold Project in Victoria, Australia. The report, prepared by qualified experts, confirms the previously announced ...
